[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Subsequently to the publication of the above article, the authors have realized that a couple of clerical errors were made when writing the article, and wish to correct these errors in a corrigendum statement. First, in the Materials and methods section on p. 2216, the final sentence of the '' subsection, the authors wish to add a further definition, so that the text reads as follows (changes highlighted in bold): '; high expression was defined as ≥40% staining of a tumor section, and low expression as <40%'. Secondly, in the Results section, '' subsection, p. 2220, right‑hand column, second paragraph, line 17, the sentence written here should have read as follows: 'The group with the expression of RET included 28.9% (26/90) of the patients, '. The authors are grateful to the Editor of for allowing them this opportunity to publish a corrigendum, and apologize to the readership of the journal for any inconvenience caused. [Oncology Reports 37: 2215‑2226, 2017; DOI: 10.3892/or.2017.5494].